Search

Search results

1. Canada should improve access to pharmaceuticals in post-COVID world

   Drugs were approved in the U.S. 469 days earlier (on average) than in Canada. ...

2. Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union

   Modern medicines not only treat illnesses that could not previously be treated, but also represent a substitution for older, less efficient, and less effective methods of treatment. Newer medicines can expand access to better health through reductions in ...

3. Minister of health makes dubious claims about Ottawa’s pharmacare plan

   Appeared in the Hill Times, July 3, 2019 With the release of the Hoskins’ report last week, national pharmacare will likely be a central issue in this fall’s federal election. It’s therefore quite worrying that federal Health Minister Ginette Petitpas ...

4. Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

   Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good. ...

5. Is Ottawa competent enough to design an efficient and effective national pharmacare program?

   A national formulary—essentially a list of drugs—is unlikely to match the comprehensive lists covered by private insurance plans. ...

6. Trudeau government's drug-pricing plan may limit access to new life-improving medicines

   Appeared in the Vancouver Province, February 21, 2019 It seems quite clear—the Trudeau government wants Ottawa to become the public insurer for prescription drugs, in part to contain drug costs. In a pre-emptive move in 2017, the government proposed ...

7. Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective

   New drugs are emerging that promise improved treatments and in some cases even cures for diseases. But these drugs are expensive, and are heightening concerns from patients and insurers (particularly public insurers) about the prices that drug companies ...

8. New pricing regulations may restrict access to innovative drugs in Canada

   We should all be concerned about Canadians who have difficulty paying for their prescription medications. Unfortunately, Ottawa’s response—to increasingly regulate the prices of all patented medicines—is misguided. Simply forcing ...